US women favour automated Pap smear tests
This article was originally published in Clinica
More than three out of four US women enrolled in managed care health plans are concerned about the accuracy and reliability of the conventional Pap smear test, says a survey released last week by CareData Reports, a New York based managed care consumer research company.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.